Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio

Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio

Dr. Reddy’s Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth up to $105 million. The generic drug portfolio involved in the deal includes around 45 commercial items, four pipeline products, as well as 40 non-marketed approved products, including a variety […]

Dr. Reddy’s Labs, Slayback sign licensing deal for Brimonidine Tartrate

Dr. Reddy’s Labs, Slayback sign licensing deal for Brimonidine Tartrate

Dr. Reddy’s Laboratories said that it has signed a licensing deal with New Jersey-based Slayback Pharma for acquiring rights in the latter’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Brimonidine Tartrate Ophthalmic Solution 0.025% is the private label equivalent of Lumify in the US. Lumify, which is an over-the-counter (OTC) eyedrop, can be used for easing the […]

Dr. Reddy’s Laboratories relaunches OTC Naproxen Sodium Tablets in US

Dr. Reddy’s Laboratories relaunches OTC Naproxen Sodium Tablets in US

Dr. Reddy’s Laboratories said that it has relaunched over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Bayer HealthCare’s Aleve, in the US market. The relaunch is as per the approval from the US Food and Drug Administration (FDA), said the Indian pharma company. According to Dr. Reddy’s Laboratories, its OTC Naproxen […]

PRESECO clinical trial for Avigan : Appili begins dosing in phase 3 Covid-19 study

PRESECO clinical trial for Avigan : Appili begins dosing in phase 3 Covid-19 study

Appili Therapeutics said that it has dosed the first participant in the phase 3 PRESECO clinical trial for Avigan tablets (favipiravir) for the oral treatment of Covid-19. The Canadian infectious disease biopharma company Appili is involving PRA Health Sciences as a clinical research organization (CRO) for administering the Covid-19 clinical trial at 47 outpatient sites. […]